BiotechTube
Home/Bolt Biotherapeutics/Grant Yonehiro
GY

Grant Yonehiro

Chief Operating Officer

Bolt Biotherapeutics

Therapeutic Areas

Oncology

Bolt Biotherapeutics Pipeline

DrugIndicationPhase
BDC-4182Gastric cancer, gastroesophageal junction cancer, and other CLDN18.2+ tumorsPhase 1
Macrophage-targeting agonist antibodyNot specified (available for partnering)Phase 1
Preclinical ISACsNot specified (available for partnering)Preclinical

Leadership Team at Bolt Biotherapeutics

WQ
Willie Quinn
Chief Executive Officer
MN
Michael N. Alonso, Ph.D.
SVP, Research
SN
Sarah Nemec
SVP, Finance and Principal Accounting Officer
BO
Brian O'Callaghan
Chair of the Board
View full Bolt Biotherapeutics profile